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Abstract
Costello syndrome (CS) may be caused by activating mutations in codon 12/13 of the
HRAS proto-oncogene. HRAS p.Gly12Val mutations have the highest transforming activity,
are very frequent in cancers, but very rare in CS, where they are reported to cause a severe,
early lethal, phenotype. We identified an unusual, new germline p.Gly12Val mutation,
c.35_36GC>TG, in a 12-year-old boy with attenuated CS. Analysis of his HRAS cDNA
showed high levels of exon 2 skipping. Using wild type and mutant HRASminigenes, we
confirmed that c.35_36GC>TG results in exon 2 skipping by simultaneously disrupting the
function of a critical Exonic Splicing Enhancer (ESE) and creation of an Exonic Splicing
Silencer (ESS). We show that this vulnerability of HRAS exon 2 is caused by a weak 3’
splice site, which makes exon 2 inclusion dependent on binding of splicing stimulatory pro-
teins, like SRSF2, to the critical ESE. Because the majority of cancer- and CS- causing
mutations are located here, they affect splicing differently. Therefore, our results also dem-
onstrate that the phenotype in CS and somatic cancers is not only determined by the differ-
ent transforming potentials of mutant HRAS proteins, but also by the efficiency of exon 2
inclusion resulting from the different HRASmutations. Finally, we show that a splice switch-
ing oligonucleotide (SSO) that blocks access to the critical ESE causes exon 2 skipping and
halts proliferation of cancer cells. This unravels a potential for development of new anti-can-
cer therapies based on SSO-mediated HRAS exon 2 skipping.
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Author Summary
HRAS was the first human proto-oncogene reported and p.Gly12Val in codon 12 the first
oncogenic mutation described. Somatic mutations in HRAS are important drivers in can-
cer, and germline mutations cause Costello syndrome. Until now, it has been believed that
the severity of mutations located in theHRAS codon 12/13 mutational hot spot sequence
is exclusively determined by the activity of the encoded proteins. Here we show that muta-
tions in exon 2 of the HRAS proto-oncogene can have a previously unrecognized effect on
splicing efficiency and thereby determine HRAS activity. We report a patient with Costello
syndrome (CS), who despite having the classical, severe, oncogenic p.Gly12Val mutation
in HRAS has a mild clinical phenotype. We show that this is due to his specific sequence
change, c.35_36GC>TG, encoding p.Gly12Val, which disrupts an ESE fundamental for
efficient splicing of exon 2. We have explored this in detail and were able to show that
HRAS exon 2 is a weak exon, which is dependent on the balance between positive and
negative splicing regulatory factors, like SRSF2 and hnRNPF/H in order to be properly
included. We show that different mutations in the mutational hot spot inHRAS codon 12
and 13 (c.34-39) affect splicing of HRAS differently, suggesting that this mechanism may
also influence their occurrence in CS and their oncogenic potential in somatic cancers.
Finally, we show that blocking access to the fundamental ESE, located in HRAS c.34-39,
using a splice switching oligonucleotide (SSOs), causes exon 2 skipping, abolishes produc-
tion of functional HRAS protein and halts proliferation of cancer cells. This shows a previ-
ously unknown weakness of theHRAS proto-oncogene, namely that exon 2 is weakly
defined and therefore is a suitable target for SSO-based therapy, thereby pointing towards
a potential new direction for therapeutic targeting of RAS in anti-cancer treatment.
Introduction
The Harvey rat sarcoma viral proto-oncogene homolog (HRAS) was the first human proto-
oncogene to be identified [1]. The HRAS protein is a GTPase, which mediates signal transduc-
tion from growth factor receptors important for cellular proliferation, growth and survival.
Somatic mutations inHRAS are present in many cancers and the vast majority of mutations
affect codons 12 and 13 (c.34-39) leading to a constitutively active protein. The c.35G>T muta-
tion (p.Gly12Val) in HRAS was the first mutation in a proto-oncogene that was implicated in
cancer [2,3] and it is the second most frequently reportedHRASmutation in human cancers
(Cosmic database: http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=HRAS). The p.Gly12-
Val mutant has the lowest GTPase activity [4] and highest transformation potential among
HRASmutants [5,6].
Germline mutations in HRAS cause Costello syndrome (CS) (MIM: 218040), which is a
congenital disease characterized by postnatal growth retardation, short stature, tumor predis-
position, developmental delay, and abnormalities of the heart (cardiomyopathy), skin and skel-
etal muscles [7].
The vast majority (75%) of CS is caused by heterozygous c.34G>A (p.Gly12Ser) activating
mutations in HRAS [8]. Heterozygous c.35G>C (p.Gly12Ala) and c.37G>T (p.Gly13Cys)
HRASmutations are also frequent in CS patients, making up 10% and 7% of alleles, respec-
tively [8]. Whereas these mutations result in a relatively homogenous phenotype, a particularly
severe, early lethal form of CS has been observed in a few patients with the less frequently
observed p.Gly12Val (encoded by c.35G>T, c.35_36GC>TT or c.35_36GC>TA), p.Gly12Asp
(c.35G>A) or p.Gly12Cys (c.34G>T) mutations [9–12]. These severe CS phenotypes are
Splicing Efficiency of ActivatingHRASMutations
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consistent with the higher transforming potential of the p.Gly12Val, p.Gly12Asp and p.
Gly12Cys mutant proteins [5] and are also reflected in the higher frequencies of these muta-
tions in cancer (Cosmic).
So far it has therefore been believed that the relative frequency of the different HRASmuta-
tions in cancer and CS simply reflects differences in the oncogenic potential of the encoded
proteins and differences in the rate they occur by spontaneous mutations. Recently, it was,
however, demonstrated that a phenomenon termed “selfish selection”may be an important
factor determining the mutation spectrum observed in CS. Selfish selection both offers an
explanation for the puzzling fact that CS has an extreme paternal bias in origin and occurs with
a frequency two—three orders of magnitude higher than expected from the background muta-
tion rate [8]. This is explainable by the fact thatHRASmutations offer different selection
advantages in male germ cells depending on their oncogenic potential, and that their propor-
tion increases with paternal age dependent on the selective advantage.
Exonic mutations may, however, also have other effects than the expected changes in the
protein, which can be predicted based on the resulting change from one codon to another
according to the genetic code. A so called “splicing code” [13], which predicts that exonic
mutations may have effects by impacting splicing regulatory elements, is beginning to emerge
as an important cause of human disease, including cancer. This was elegantly demonstrated in
a study by Supek and co-workers, who showed that synonymous mutations frequently act as
driver mutations in cancer by altering exonic splicing regulatory motifs [14]. In particular, it
was demonstrated that cancer-associated synonymous mutations frequently create exonic
splicing enhancers (ESEs) and destroy exonic splicing silencers (ESSs) which regulate oncogene
splicing in tumors. Additionally, expression and activity of splicing regulatory factors, like the
SR-proteins and the hnRNP proteins are often dysregulated in cancer leading to aberrant splic-
ing of oncogenes and tumor suppressor genes. A prominent example is the SRSF2 splicing reg-
ulatory factor, which is frequently mutated to a dominant negative form in myelogenic diseases
[15]. Other important splicing regulatory factors such as SRSF1, SRSF3 and SRSF6 have been
described as potent oncogenes [16–18], underscoring the importance of dysregulated splicing
in cancer.
Here we demonstrate for the first time thatHRAS exon 2 is a vulnerable exon, which is
dependent on binding of splicing regulatory proteins to ESEs in order to be correctly included
in the HRASmRNA. Importantly, we show that a mutation in the codon for Glycine 12 (c.34-
39) can abrogate formation of constitutively active p.Gly12Val HRAS in a CS patient by medi-
ating pronounced exon 2 skipping. Moreover, we show that this vulnerability ofHRAS exon 2
splicing can be exploited by employing splice switching oligonucleotides (SSOs) to induce
HRAS exon 2 skipping. This provides proof of principle for a new mechanism for knocking out
oncogenic HRAS, which may be used therapeutically to treat cancer.
Results
We investigated a 12-year-old boy with an attenuated CS phenotype (see online methods).
Sequence analysis of his DNA from multiple tissues showed a heterozygous c.35_36GC>TG
germline mutation that was predicted to result in p.Gly12Val (Fig 1) There was no evidence
of mosaicism (S1 Fig). Presently only a few individuals with CS with a p.Gly12Val mutation
(c.35G>T, c.35_36GC>TT, c.35_36GC>TA) have been reported and all had a very severe
clinical presentation, with death typically within the first months of life [9,10].
Because mosaicism did not explain the mild clinical presentation of the severe p.Gly12Val
mutation in this boy, RNA from lymphocytes was examined and showed extensive exon 2 skip-
ping, and showed that the c.35_36GC>TGmutation was nearly absent in correctly spliced
Splicing Efficiency of ActivatingHRASMutations
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HRASmRNA (Fig 1). Low levels of exon 2 skipping were also observed in cells from controls
and individuals with CS heterozygous for other HRASmutations, indicating that exon 2 may
be difficult to splice efficiently. Consistent with this, different human tissues also show low lev-
els ofHRAS exon 2 skipping and the amount varies between tissues, possibly reflecting tissue
specific differences in the splicing regulatory factors which mediate exon 2 inclusion (S2 Fig).
An mRNA without exon 2 will not produce a functional protein as the switch domains, switch
I (amino acids 32–38) and switch II (amino acids 59–67), are fundamental for RAS-GTP/GDP
binding, and thus for biological function. Exon 2 (amino acids 1–37) encodes a major part of
the switch I domain. In particular threonine 35, which binds the terminal phosphate (γ-phos-
phate) of GTP in the active site, is encoded by exon 2. Therefore, if a protein were to be pro-
duced from an mRNA lacking exon 2 it would not be functional. Additionally, the normal
ATG start codon is located in exon 2. A potential alternative in-frame ATG start codon is
located in exon 3, but it’s use would produce a protein with a deletion of 66 amino acids from
the amino terminal end, and thereby exclude both switch I and switch II. Consequently, loss of
HRAS activity due to exon 2 skipping from the c.35_36GC>TGmutation can explain the
attenuated phenotype in the individual with CS.
Fig 1. Analysis of patient DNA and cDNA. (a) RT-PCR analysis of lymphocyte cDNA from four unrelated controls and three individuals with
Costello syndrome (CS), caused by heterozygosity for c.34G>A, c.37G>T and c.35_36GC>TG (index individual), revealed pronounced exon 2
skipping in the index individual. The low levels of exon 2 skipping observed in controls and individuals with CS with other genotypes indicates
that exon 2 is inefficiently spliced. RPL13A was amplified as a control. (b) Comparison of sequence analysis of genomic DNA and lymphocyte
cDNA from the index individual, shows that wild type and c.35_36GC>TG alleles are equally present in genomic DNA, but not in full length
cDNA. (c) Chromatograms from sequencing of the full length band (exon 2 inclusion) from lymphocyte cDNA in forward and reverse direction
from individuals with CS heterozygous for c.35_36GC>TG, c.34G>A and c.37G>T.
doi:10.1371/journal.pgen.1006039.g001
Splicing Efficiency of ActivatingHRASMutations
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Since individuals with CS with other HRASmutations, c.35G>T, c.35_36GC>TT and
c.35_36GC>TA encoding the p.Gly12Val mutant protein have suffered from a very severe CS
phenotype, we investigated the effect of these mutations on HRAS exon 2 splicing using a
HRASminigene. Transfection of the wild type and mutant minigenes into HepG2 cells con-
firmed that the c.35_36GC>TG mutation by itself causes high levels of exon 2 skipping,
whereas the c.35_36GC>TT and c.35_36GC>TA p.Gly12Val mutations cause a low or modest
increase in exon 2 skipping, respectively (Fig 2). The severe p.Gly12Val, c.35G>T mutation
did not increase exon 2 skipping. Taken together, these data show that different nucleotide
changes in codon 12 (c.34-36) of HRAS exon 2 can regulate HRAS activity by affecting the effi-
ciency ofHRAS exon 2 inclusion into mRNA during pre-mRNA splicing. In their examination
of the spontaneous mutation rate and selective advantage of HRASmutations in the paternal
germline, Giannoulatou and co-workers [8] did not observe the c.35_36GC>TG mutation,
Fig 2. p.Gly12Val mutations in codon 12 ofHRAS exon 2 affect splicing differently. (a) Displays the
HRASminigene construct and the wild type and mutant sequences. TheHRASminigene consisted of the first
four HRAS exons (including the natural intronic sequences) cloned into the polylinker of a pcDNA3.1+ vector.
(b) Representative results from HepG2 cells transfected with wild type and mutant minigenes. Splicing
analysis by PCR amplification and agarose gel electrophoresis reveals extensive exon 2 skipping from
c.35_36GC>TG construct and moderate exon 2 skipping from c.35_36GC>TA construct. The lane labelled
“Vect.” shows the results from a sample transfected with an empty p.cDNA3.1+ vector. (c) Quantification of
the exon 2 inclusion rate from triplicate transfections using a fragment analyzer. Numbers are % inclusion.
Calculations are based on molar ratios.
doi:10.1371/journal.pgen.1006039.g002
Splicing Efficiency of ActivatingHRASMutations
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whereas the c.35G>T, c.35_36GC>TT and c.35_36GC>TA p.Gly12Val mutations were
observed. This is consistent with their hypothesis of selective advantage contributing to the
observed abnormally high mutation rates in sperm, since the c.35_36GC>TG mutation would
be selected against due to its deleterious effect on exon 2 inclusion.
Pre-mRNA splicing of constitutive exons with weakly defined splice sites is dependent on a
delicate balance between exonic splicing enhancers (ESE) and exonic splicing silencers (ESS)
[13,19]. ESEs bind positive splicing factors, typified by the serine/arginine-rich (SR) proteins
[20]. In contrast, ESSs bind proteins from the heterogeneous nuclear ribonucleoprotein
(hnRNP) family [21], which inhibits splicing. Consequently, a mutation which either disrupts/
weakens a binding motif in an ESE or creates/strengthens an ESS can result in exon skipping if
the exon is weakly defined. In silico analysis showed that HRAS exon 2 is weakly defined due to
a weak 3’ splice site with a non-consensus G nucleotide at position -5 in intron 2 and a GGG
triplet at positions -14 to -16 disrupting the polypyrimidine tract (Fig 3). A short polypyrimi-
dine tract is difficult to recognize for the U2AF65 splicing factor, and furthermore GGG triplets
can bind hnRNPF/H family proteins, which could compete with U2AF65 binding and thereby
decrease 3’-splice site splicing efficiency [22]. We hypothesized that this weak 3’ splice site
makes inclusion of HRAS exon 2 dependent on the binding of splicing regulatory proteins to
ESEs and that this is disrupted by the c.35_36GC>TGmutation.
In order to make exon 2 recognition independent of the ESE/ESS balance we strengthened
the weak 3’ splice site by replacement of the non-consensus G and the GGG triplet in the poly-
pyrimidine tract with consensus T nucleotides (Fig 3). This improved splicing from the wild
typeHRASminigene and abolished exon 2 skipping from the c.35_36GC>TG mutant. Inter-
estingly, c.35_36GC>TG creates a known splicing inhibitory motif (GTGGGTG) (S3 Fig),
which binds proteins from the hnRNPF/H family. There are several examples from other
genes where single nucleotide substitutions have created or abolished this motif in a weak con-
stitutive exon causing aberrant splicing and disease [22–27] (S3 Fig). This suggests that the
c.35_36GC>TGmutation creates an hnRNPF/H binding ESS, which inhibits inclusion of
exon 2. Consistent with this hypothesis, replacement in the HRASminigene of the wild type
sequence c.34-39 with known hnRNPF/H binding ESS motifs results in exon 2 skipping (S4
Fig). These motifs have previously been demonstrated to cause exon skipping in other genes
[26,28]. Moreover, introduction of a single c.36C>Gmutation, creating the hnRNPF/H
(DGGGD) binding motif [29] also causes complete exon 2 skipping (S4 and S5 Figs) under-
scoring the importance of c.36G in disruption of splicing. However, both introduction of CC at
position c.37-38 (S4 Fig) and deletion of nucleotides c.32-37 (Fig 3) in the wild type cause exon
2 skipping, indicating that a fundamental ESE is also present in this region of wild type HRAS
exon 2.
We used two different splicing reporter minigenes [30,31] to demonstrate that this part of
HRAS exon 2 harbors ESEs, which can drive splicing in other genomic contexts, and that exon
inclusion is abolished by the c.35_36GC>TGmutation (S5 Fig). Interestingly, testing of the
c.35G>T mutant sequence indicated that it results in more efficient splicing than the wild type
sequence. This is consistent with the results from the HRASminigene and indicates that this
mutation may improve splicing. ESE finder analysis [32] also suggests that the region around
c.35 harbors potential binding sites for the SRSF1 and SRSF2 splicing stimulatory proteins,
which usually bind ESEs to stimulate splicing. The c.35_36GC>TG mutation directly abolishes
SRSF1 motifs, but does not directly affect the SRSF2 motif, whereas a deletion of nucleotides
c.32-37 disrupts both the SRSF1 and SRSF2 motifs (Fig 3). RNA affinity purification employing
wild type and c.35_36GC>TG mutant RNA oligonucleotides combined with ITRAQ labeling
followed by MS/MS analysis indicated that the c.35_36GC>TGmutation increases binding
of hnRNP F/H proteins and decreases binding of SRSF2, but not SRSF1 and this could be
Splicing Efficiency of ActivatingHRASMutations
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demonstrated by western blot analysis (Fig 4). Binding of hnRNPF/H proteins may also disrupt
binding of SRSF2 and other splicing stimulatory proteins to an overlapping ESE.
Since hnRNPF/H binding to GGG triplets in a pre-mRNA is cooperative and synergistic
[29], mutations creating new GGG triplets inHRAS exon 2 are likely to inhibit splicing by act-
ing in synergy with pre-existing GGG triplets, such as the flanking GGG triplets and the GGG
triplet in the weak 3’-splice site.
Interestingly, expression of hnRNPF/H proteins is low in cardiomyocytes [33], suggesting
that inclusion of c.35_36GC>TGmutant exon 2 could be high in the heart from our patient.
Taken together our data suggest that c.35_36GC>TG simultaneously disrupts an ESE and
creates a strong hnRNPF/H binding ESS (S6 Fig). Consistent with this, siRNA mediated knock
down of SRSF2 caused exon 2 skipping both from the wild typeHRASminigene and from
endogenous HRAS in T24 and HepG2 cells (Figs 4 and S7), whereas SRSF1 knockdown had no
effect onHRAS exon 2 inclusion (S8 Fig). This does of course not exclude that other splicing
regulatory factors may also bind to theHRAS ESE and stimulate exon 2 inclusion.
To further substantiate that HRAS exon 2 skipping leads to inactivation of HRAS and that
an ESE fundamental for HRAS exon 2 inclusion is present in the region harboring c.35G, we
designed a splice switching oligonucleotide (SSO) that would block binding of splicing regula-
tory proteins to the ESE. Consistent with this proposed effect, the SSO caused exon 2 skipping
from the wild type HRASminigene. Interestingly, the effect of the SSO was alleviated when the
Fig 3. The weak 3’ splice site inHRAS exon 2 has a non-consensus G nucleotide and a GGG triplet in
the polypyrimidine tract. (a) Representative results from HepG2 cells transfected with wild type and
c.35_36GC>TGmutant minigenes holding either a weak wild type 3’ splice site or an optimized 3’-splice site.
Introducing a strong 3’ splices site eliminates skipping of exon 2 indicating that the vulnerability of exon 2 is
determined by the weak 3’ splice site. The lane labelled “Vect.” shows the results from a sample transfected
with an empty p.cDNA3.1+ vector. (b) Displays the HRASminigene construct. Sequences of the wild type
and optimized 3’-splice sites are displayed. Scores based on MaxEnt calculations for wild type and optimized
3’-splice sites are listed. The mean score for all 3’-splice sites in theHRAS gene is shown. (c) Wild type,
c.35_36GC>TGmutant and 6 bp deletion sequences are shown. The scores from ESE-finder and generation
of an inhibitory GGG triplet are shown. (d) When a 6 bp deletion is introduced, exon 2 is completely skipped.
The lane labelled “Vect.” shows the results from a sample transfected with an empty p.cDNA3.1+ vector.
doi:10.1371/journal.pgen.1006039.g003
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3’-splice site was strengthened in the minigene (Fig 5). This substantiates that vulnerability of
exon 2 is determined by the weak 3’-splice site.
Next we demonstrated that the SSO causes exon 2 skipping from the endogenousHRAS
gene in both T24 and HepG2 cells. This was reflected in reduced levels of HRAS protein and by
decreased growth and proliferation (Fig 5). This indicates thatHRASmRNA with exon 2
skipped is either not translated due to the lack of the normal ATG start codon, or if a protein is
produced from an alternative start codon the resulting protein is unstable. These data show
that skipping of HRAS exon 2 leads to decreased growth and proliferation consistent with
reduced HRAS activity. Moreover, they confirm that an important ESE is located around posi-
tion c.35 and that SSO-mediated blocking of access to this ESE reduces exon 2 inclusion.
Because recognition of ESEs by splicing stimulatory proteins is highly sequence specific, it is
likely that other sequence variants in codon 12 and 13 may influence exon 2 inclusion and play
a role in determining their phenotypic consequences. Consequently, we employed minigene
transfection of T24 and HepG2 cells to test codon 12 and 13 mutations, which are known to
cause CS [8] or cancer (Cosmic) for their effect on exon 2 inclusion (Fig 6). This showed that
mutations like c.35G>C and c.37G>T, which are frequent in CS, but infrequent in cancer,
have a relatively high level of exon 2 skipping, potentially attenuating their deleterious effect,
whereas mutations like c.35G>A and c.35G>T, which are very frequent in cancers and rare in
CS, have a high level of exon 2 inclusion (Fig 6).
In line with this, it is quite obvious that the c.35_36GC>TGmutation despite encoding the
most severe mutant protein, p.Gly12Val, would most likely never be observed in cancer
(c.35_36GC>TG is not present in the Cosmic database) due to the high level of exon 2
Fig 4. Binding analysis of SRSF2 and hnRNPF/H. (a) Biotinylated RNA oligonucleotides with either wild
type or c.35_36TG HRAS sequence were incubated with HeLa nuclear extracts (NE). Biotinylated RNA
oligonucleotides bind streptavidin coated beads allowing identification of protein-RNAmotif interactions from
NE. The beads are superparamagnetic and RNA binding proteins are purified when an external magnetic
field is applied. (b) Western blot analysis shows that the c.35_36GC>TGmutation increases binding of
hnRNPF/H proteins and decreases binding of SRSF2. (c) siRNAmediated knock down of SRSF2 causes
exon 2 skipping both from the wild typeHRASminigene and endogenous HRAS in HepG2 cells. (d) Western
blot analysis was used to confirm SRSF2 knock down.
doi:10.1371/journal.pgen.1006039.g004
Splicing Efficiency of ActivatingHRASMutations
PLOS Genetics | DOI:10.1371/journal.pgen.1006039 May 19, 2016 8 / 18
skipping and conversely, c.35G>T, which encodes an identical protein, is the second most fre-
quent mutation in cancer and very rare in Costello syndrome due to the very efficient inclusion
of exon 2.
The most frequent CS mutation, c.34G>A, has a very modest, nearly neutral, negative effect
on exon 2 inclusion and its high occurrence in both CS and cancer is thus probably mainly due
to a high mutation rate (due to CpG hypermutability) and a modest transforming potential of
the encoded p.G12S protein.
Discussion
We show that a particular mutation, c.35_36GC>TG, which encodes the prototypical onco-
genic, constitutively active p.G12V HRAS protein, causes exon 2 skipping in an individual with
CS with an attenuated clinical phenotype. This key finding demonstrates, in vivo, in a patient
Fig 5. SSO-mediated skipping ofHRAS exon 2. (a) T24 bladder cancer cells, which harbor the c.35G>T mutation, were transfected with
HRASminigenes with either a wild type or an optimized 3’ splice site and treated either with an SSO (SSO-A) that blocks access to the ESE or a
scrambled control SSO. SSO-A treatment mediates exon 2 skipping from the wild type HRASminigene, but this is alleviated when optimizing the
3’ splice site. (b) SSO-A treatment causes nearly complete skipping of endogenous HRAS exon 2 in T24 cells. (c) Western blot analysis
confirmed reduced levels of HRAS protein following SSO-A treatment. (d) Quantification of cell viability after SSO-A treatment by WST-1 assay
demonstrates that it decreases viability of T24 bladder cancer cells. (e) xCelligence real time monitoring of proliferation of T24 bladder cancer
cells. Cells were treated with either SSO-A or control SSO at two concentrations (20 nM or 30 nM). When treated with SSO-A cell viability and
growth is decreased.
doi:10.1371/journal.pgen.1006039.g005
Splicing Efficiency of ActivatingHRASMutations
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that exon 2 skipping leads limited production of the constitutively active oncogenic HRAS,
thereby attenuating clinical symptoms. Simultaneously, this points to a previously unrecog-
nized “Achilles heel” of the HRAS gene, namely that exon 2 is weakly defined due to a subopti-
mal 3’splice site. It’s inclusion in the mRNA is therefore dependent on binding of splicing
stimulatory proteins, like SRSF2 to ESEs, and that binding of splicing inhibitory proteins, like
hnRNPF/H to ESSs is avoided. ThusHRAS exon 2 inclusion can be affected by mutations alter-
ing the balance between ESEs and ESSs and this could in turn also result in cell type specific dif-
ferences in splicing efficiency dependent on the relative levels/activities of splicing regulatory
proteins, like SRSF2 or hnRNPF/H in the relevant tissue. Consistent with this, we show that
mutations in codon 12 and 13 (c.34-39) impact exon 2 inclusion differently, and thatHRAS
exon 2 splicing efficiency is different (e.g. T24 and HepG2 cells). Thus, our results illustrate
that the oncogenic effect of different mutations inHRASmay be determined also by their effect
on exon 2 splicing efficiency. This adds an additional layer to the complex interpretation of the
molecular consequences of mutations in HRAS exon 2. We posit that a delicate balance exists
between the mutability of the different nucleotides, the resulting efficiency of exon 2 inclusion,
Fig 6. Mutations in codon 12 or 13 of HRAS exon 2 affect splicing differently. (a,b) HepG2 (top) or T24
(bottom) cells were transfected with HRASminigenes harboring different sequence variants in positions c.34-
38. The frequencies of the mutations in Costello syndrome according to Giannoulatou and co-workers [8] and
in cancer according to Cosmic database are displayed. For cancer the numbers are displayed with skin
cancers included or excluded due to the extremely high occurrence of the c.37G>Cmutation in skin cancer.
The original scoring of the transforming potential of the mutants in two studies are displayed—A is from
Seeburg and co-workers [5]; B is from Fasano and co-workers [6]. Quantitative data for exon 2 inclusion
(molar ratio) were obtained from triplicates of duplicate transfections using the Agilent 2100 Bioanalyzer. It is
worth noting that there is a clear difference in the overall splicing efficiency between T24 cells and HepG2
cells, which is consistent with the reported low levels of hnRNPF in HepG2 cells [34].
doi:10.1371/journal.pgen.1006039.g006
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and the oncogenic effect of the encoded mutant protein. We postulate that the observed fre-
quencies of the various mutations in codon 12 and 13 in CS and cancers are a result of this
balance.
This has clear implications for our understanding of the correlation between genotype and
phenotype in diseases caused byHRASmutations and highlights the general importance of
the “splicing code” [13], by providing a striking example on how exonic mutations, like
c.35_36GC>TG, can affect splicing and have dramatically different effects than those predicted
based solely on the genetic code.
Finally, we show that this previously unknown weakness of theHRAS gene points to a new
mechanism for knocking out oncogenic HRAS by employing SSOs that block binding of the
required splicing regulatory factors, resulting in exon 2 skipping and decreased growth of can-
cer cells. SSOs targetingHRAS exon 2 splicing may represent a new therapeutic approach either
when used alone or in combination with other therapies. In contrast to traditional drugs, SSOs
are highly specific for a single gene and there are currently promising clinical trials employing
SSOs for treating human disease. SSOs that are able to inhibit tumorigenesis in vivo by altering
splicing of genes, like Bcl-X, STAT3 andMDM4 have been reported [35–37]. A particularly
appealing characteristic of SSOs is that delivery of several different SSOs targeting different
cancer genes, like those mentioned above, could be performed simultaneously using the same
delivery method. In this way multiple oncogenic mechanisms could be targeted in a single
approach. Our data suggest that SSO-based therapy targeting HRAS could also be included in
such a future strategy.
Materials and Methods
Ethics statement
Written informed consent was obtained from all participants and the study was approved by
the Institutional Review Board at the University of Utah (IRB#00013747).
Clinical review
This 12-year-old boy had a history of hypertrophic cardiomyopathy status post septal myo-
mectomy at 11 months of age. An echocardiogram at 12 years showed only mild septal hyper-
trophy with trace aortic insufficiency. A Nissen fundoplication and gastrostomy tube (GT)
placement were performed at 2 months of age due to swallowing dysfunction and aspiration.
The GT was used intermittently for 10 years but subsequently removed. He had one general-
ized seizure at 1 year without recurrence. A brain MRI at 17 months showed mild enlargement
of the lateral and third ventricles with a mild Chiari I malformation. He received growth hor-
mone injections starting at 9 years of age due to growth hormone deficiency. At 12 years,
growth parameters were as follows: height = 142 cm (10th centile), weight = 32 kg (5th centile),
and head circumference = 55.5 cm (75th centile). Other clinical features included ptosis, tele-
canthus, posteriorly rotated ears, deviated nasal septum, dental crowding, retrognathia, slightly
large appearing hands without significant skin redundancy/deep creases or ulnar deviation, pes
planus, an asymmetric anterior chest wall deformity, hyperflexibility, and mild kyphosis. He
had one large nevus on his leg but otherwise did not have any additional dermatologic abnor-
malities and his hair appeared normal. There was no history of malignancies. He had mild
developmental delay with good verbal skills and a full scale IQ of 76. He required resource clas-
ses for approximately 40% of his classes but was in the mainstream educational system for the
remaining classes with some modification.
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HRASminigenes
Genomic DNA was used for PCR amplification of a fragment of the human HRAS gene
(NC_000011.9) encompassing exons 1–4 using Platinium Pfx DNA Polymerase supplemented
with enhancer solution (Invitrogen) and primers HRAS1sNheI: 5’-GGCCCCGCTAGCAG
TCGCGCCTGTGAA-3’ and HRAS1asXhoI: 5’-GTGAAGGACTCGAGTGACGTGCCCAT-
3’. The amplified fragment was digested with NheI and XhoI and cloned into the polylinker of
pcDNA.3.1+ (Invitrogen). Mutations were introduced by site-directed mutagenesis using stan-
dard methods either by the authors or by GeneScript Inc. (GenScript, Piscataway, NJ, USA).
All plasmids were sequenced by GATC Biotech AG (Germany) in order to exclude any PCR
derived errors.
RHCglo and pSXN splicing reporters
HRAS exon 2 and variant double stranded DNA oligonucleotides corresponding to c.13_47 of
HRAS exon 2 were inserted into the alternatively spliced second exon in the RHCglo splicing
reporter minigene [31]. To generate pSXN constructs [30] we used sense and antisense
oligonucleotides with desired sequences. The integrity of all constructs was confirmed by
sequencing.
Transient transfections of HepG2 and T24 cells and splicing analysis
T24 human urinary bladder cancer cells were obtained from Coriell Institute (https://catalog.
coriell.org/). HepG2 human hepatocellular carcinoma cells were obtained from American
Type Culture Collection (ATCC) (http://www.lgcstandards-atcc.org/en.aspx). HepG2 or T24
cells were grown under standard conditions using 10% RPMI (Lonza RPMI 1640 added 10%
FCS, glutamine (100x) and pen/strep (1000 U/ml)) or 5% RPMI (Lonza RPMI 1640 added 5%
FCS, glutamine (100x) and pen/strep (1000 U/ml)), respectively. Twenty-four hours before
transfection the cells were seeded 9.6 cm2 6-well plates (Nunc) at a density of 1.7×105 (HepG2)
or 1.2×105 (T24) in 2 ml 5% or 10% RPMI (25% confluence) and grown O.N. to a density of
50% confluence on the day of transfection. Cells were transfected with a total DNA amount of
800 ng per well using X-tremeGene 9 DNA Transfection Reagent (Roche). Cells were trans-
fected with 600 ng of plasmid DNA of interest and co-transfected with 200 ng MCAD 362T
plasmid [19] as positive control. Forty-eight hours after transfection cells were harvest for
RNA using Isol-RNa Lysis Reagent (AH Diagnostic) and RNA isolated using phenol-chloro-
form extraction. cDNA synthesis was performed using Superscript VILO cDNA Synthesis Kit
(Invitrogen). Splicing analysis was carried out by PCR amplification and agarose gel electro-
phoresis. ForHRAS constructs we used a specific primer T7-EXT: 5’- ATTAATACGACT
CACTATAGGG-3’ and a primer spanning the exon 3-exon 4 junction of theHRAS gene
(RasEx4Ex3: 5’-CGTTTGATCTGCTCCTGTAC-3’). For the RHCglo constructs we used
primers RSV5U: 50-CATTCACCACATTGGTGTGC-30 and TNIE4: 50-AGGTGCTGCCGC
CGGGCGGTGGCTG-30. For the pSXN construct we used primers pSXN12s2: 5'-AAGGT
GAACGTGGATGAAGTTGGTGGTG-3' and pSXN13as: 5'-CCCACGTGCAGCCTTTGA
CCTAGTA-3'. All transfections were performed in triplicates.
RNA affinity purification of nuclear proteins
Affinity purification of RNA binding proteins was performed with 3’-biotin coupled RNA oligonu-
cleotides (DNA Technology, Denmark) as previously described [19]. The sequences of the RNA
oligonucleotides were: HRAS-wt (50-GUCGACUGGUGGGCGCCGGCGGUGUGGGCAAGAG
UG-30) and HRAS-mut (50-GUCGACUGGUGGGCGCCGUGGGUGUGGGCAAGAGUG-30)
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corresponding to position c.17_52 of HRASmRNA. For each purification 100 pmol of RNA
oligonucleotide was coupled to 100 μl of streptavidin-coupled magnetic beads (Invitrogen)
and incubated with HeLa nuclear extract (Cilbiotech S.A., Belgium). Eluted proteins were
analyzed by western blotting using a monoclonal anti-SRSF2 antibody (sc-041550 fromMilli-
pore) or a polyclonal anti-hnRNPF/H (sc-15387 from Santa Cruz).
Splice shifting oligonucleotide design
SSOs were phosphorothioate oligonucleotides with 2'-O-methyl modification on each sugar
moiety (DNA-technology, Denmark). HRAS-SSO-A: 5’-CGCACUCUUGCCCACACCGC
CGGCG-3’ (Nucleotides corresponding to pos. c.51_30) and control SSO: 5’-GCUCAAUAU
GCUACUGCCAUGCUUG-3'.
Reverse transfection of HepG2 or T24 cells with SSOs
Approximately 3×105 HepG2 or T24 cells were reverse transfected with 50 pmol (20 nM), 75
pmol (30 nM), 100 pmol (40 nM) or 250 pmol (100 nM) of SSOs using Lipofectamine RNAi-
MAX transfection reagent (Invitrogen). Forty-eight hours after transfection cells were harvest
for RNA using Isol-RNa Lysis Reagent (AH Diagnostics, Denmark) and RNA isolated using
phenol-chloroform extraction or analyzed by the WST-1 viability assay. cDNA synthesis was
performed using Superscript VILO cDNA Synthesis Kit (Invitrogen). For exogenous splicing
analysis cells were transfected with minigene constructs 24 hours after SSO treatment. Splicing
analysis of endogenousHRAS transcripts were performed by PCR with primers located in exon
1 (HRAS1sNheIS: 5’-GGCCCCGCTAGCAGTCGCGCCTGTGAA-3’) and a primer spanning
the exon 3-exon 4 junction of theHRAS gene (RasEx4Ex3AS: 5’-CGTTTGATCTGCTCCTG
TAC-3’). For exogenous splicing analysis we used primers T7-EXT: 5’- ATTAATACGACT
CACTATAGGG-3’ and RasEx4Ex3AS: 5’-CGTTTGATCTGCTCCTGTAC-3’. All experi-
ments were performed at least in triplicate. To check the effect of SSO treatment on HRAS pro-
tein levels, protein was extracted for SDS-PAGE and western blotting using a mouse polyclonal
anti-HRAS antibody (SAB1405964 from Sigma-Aldrich) or an rabbit anti-beta actin antibody
(ab8229 from AbCam).
Determination of cell viability
Cell viability was determined by the WST-1 viability assay in 96 well plates following the man-
ufacturer’s instructions (Roche). Approximately 3×105 T24 cells/well were reverse transfected
with 30nM of SSOs using Lipofectamine RNAiMAX transfection reagent (Invitrogen) and
incubated for 72h. Absorbance was measured on a VERSAmax tunable microplate reader
(Molecular devices) at 3, 4 and 5 hours after addition of the WST-1 reagent. Non-treated cells,
cells treated only with Lipofectamine RNAiMAX transfection reagent (Invitrogen) and a non-
targeting scrambled SSO served as controls. All WST-1 viability assays were performed at least
in triplicate.
siRNAmediated knock down
Knockdown of SRSF1 or SRSF2 was performed using 100 pmol siRNA SMARTpools (Thermo
Scientific) and scrambled control. For endogenous knock down T24 and HepG2 cells were
grown to a density of 60–80% confluence when treated with siRNA using Lipofectamine RNAi-
MAX transfection reagent according to manufacturer’s instructions. Forty-eight hours after
transfection cells were harvest for RNA using Isol-RNa Lysis Reagent (AH Diagnostics) and
RNA isolated using phenol-chloroform extraction or protein was extracted for SDS-PAGE and
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Western blotting. For exogenous knock down cells were transfected with minigene constructs
24 hours after siRNA treatment.
Xcelligence assay
Approximately 9000 T24 cells/well were reverse transfected with 20 nM or 30 nM of SSO-A or
control SSO using Lipofectamine RNAiMAX transfection reagent (Invitrogen) and cell index
was continuously monitored for 140 h. Real-time proliferation analysis was conducted using E
plates (Roche, Basel, Switzerland) and xCELLigence kinetic Systems (ACEA Biosciences, San
Diego, CA). The xCELLigence software (RTCA 1.2) was used to collect impedance measure-
ments (reported as Cell Index) every 10 min for up to 72 hours.
Real-time qPCR
Real-time (RT) qPCR and analysis were performed using a LightCycler with software version
1.5.1.62 (Roche). The RT qPCR master mix was prepared using the FastStart Essential DNA
Green Master (Roche). For quantification of totalHRAS we used primers HRASEX1S: 5’-
CAGTCGCGCCTGTGAACGGTGG-3’ and HRASEX3-2AS: 5’-CCTGCTTCCGGTAG
GAATCCTCTATAGTGGG-3’. For exon 2 skipping analysis we used primers HRASEX1-3S:
5’-CGCGCCTGTGAACGGATTCC-3’ and HRASEX4-Ex3-QPCR2AS: 5’-CACCCGTTT
GATCTGCTCCTGTACT-3’.
Supporting Information
S1 Fig. Sequence analysis ofHRAS exon 2 in genomic DNA from different tissues. Four dif-
ferent human tissues (blood, cheek swab, hair and urine) from index individual with Costello
syndrome were sequenced for HRAS exon 2.HRAS sequencing identified a c.35_36GC>TG
(p.G12V) mutation in all tissues sampled without evidence of mosaicism.
(TIF)
S2 Fig. Analysis ofHRAS exon 2 skipping in cDNA from different human tissues. (a)
cDNA from eight different human tissues was tested for HRAS exon 2 skipping. Each tissue
displayed a low level ofHRAS exon 2 skipping, which varied between tissues. Primers located
in exon 1 (HRAS1sNheIS) and spanning the exon 4–3 junction (RasEx4Ex3AS) allows simulta-
neous detection of products with and without exon 2 included. A primer set specific for the
exon 2 skipped (HRASEX1-3S and RasEx4Ex3AS) was used to amplify only the exon skipped
product. RPL13A was amplified as a control. H; Heart, B; Brain, PI; Placenta, Lu; Lung, Li;
Liver, SM; Skeletal muscle, Ki; Kidney, Pa; Pancreas. (b) QPCR analysis for totalHRASmRNA
(top) using primers HRASEX1S and HRASEX3-2AS or exon 2 skipping (bottom) using primers
HRASEX1-3S and HRASEX4-Ex3-QPCR2AS was performed in samples from 20 different
human tissues and normalized to RPL13A (Nearly identical data were obtained when we used
the TBP gene for normalization instead).
(TIF)
S3 Fig. Analysis of disease-causing splicing regulatory motifs having similar architecture as
the one observed inHRAS exon 2. The Fig shows alignment of the sequence surrounding the
c.35_36GC>TGmutation with 11 nucleotides flanking sequence to each side. The conserved
splicing silencer motif (GTGGGTG) is boxed in red. Relevant sequences from the genes are
listed with disease-causing variations marked in red. The genes listed are CHRNA1, ACADSB,
HEXB, INSR and FVIII. In intron 3 of CHRNA1 a disease-causing mutation disrupts a GGG
triplet located in the polypyrimidine tract of the 3’ splice site flanking the non-functional alter-
native exon P3A, thereby excluding binding of hnRNPF/H proteins and causing aberrant exon
Splicing Efficiency of ActivatingHRASMutations
PLOS Genetics | DOI:10.1371/journal.pgen.1006039 May 19, 2016 14 / 18
inclusion [25]. Disease causing mutations in exon 10 of ACADSB andHEXB exon 12, which
also create this GTGGGTGmotif, result in exon skipping and disease [22,23,26]. The core
GTGGGTG motif created by the c.35-36 mutation is also found in the insulin receptor gene
(INSR) where hnRNPF binding to this element in intron 10 is involved in regulating alternative
splicing of exon 11 [27]. Additionally, a C>T substitution in exon 19 of FVIII also creates this
motif TGGTGGGTGG and causes exon skipping [24]. This suggests that the c.35_36GC>TG
mutation creates an hnRNPF/H binding ESS, which inhibits inclusion of exon 2. Since
hnRNPF/H binding to GGG triplets in a pre-mRNA is cooperative and synergistic [29], it is
likely, that hnRNPF/H binding to the created ESS is synergistic with other flanking GGG trip-
lets (underscored) and that this also facilitates binding of hnRNPF/H to the GGG triplet in the
weak polypyrimidine tract and that this contributes to the exon skipping effect. CHRNA1: cho-
linergic receptor, nicotinic, alpha 1; ACADSB: short/branched chain acyl-CoA dehydrogenase;
HEXB: hexosaminidase B (beta polypeptide); INSR: insulin receptor; FVIII: Factor (F) VIII.
(TIF)
S4 Fig. Demonstrating that both creation of hnRNPF/H binding motifs and disruption of
the ESE motif in HRAS exon 2 causes skipping. (a) Displays the HRASminigene construct
and replacement of the wild type sequence c.34-39 with known hnRNPF/H binding ESS
motifs (CAGGGT or TAGGGA). A single c.36C>Gmutation was also introduced to create
the hnRNPF/H (DGGGD) binding motif [29]. A dinucleotide c.37_38GG>CC mutation was
introduced to disrupt the ESE motif. (b) Representative results from cells transfected with
wild type and mutant minigenes. Agarose gel electrophoresis reveals exon 2 skipping both
when an hnRNPF/H motif is introduced and when the ESE is disrupted by introduction of
c.37_38GG>CC.
(TIF)
S5 Fig. TestingHRAS exon 2 sequences in two splicing reporter minigenes. (a) Schematic
overview of the RHCglo splicing reporter and construct used in this study, harboring either
HRAS wild type sequence or c.35G>T, c.35G>C, c.35_36GC>TG or c.35_36GC>TT mutant
sequences (top). The second exon in the RHCglo splicing reporter is immediately flanked
upstream and downstream by the last and first 91 and 73 nucleotides of human β-globin intron
1, respectively. The distal upstream segment of intron 1 contains introns 1 and 3 of chicken
skeletal troponin I (sTNI), and the distal downstream region of intron 2 contains the last 364
nucleotides of sTNI intron 3. Inclusion of the alternatively spliced second exon is critically
dependent on the balance between ESEs and ESSs in the inserted sequence. PCR analysis of
splicing of RHCglo-HRAS constructs in HepG2 cells (bottom). (b) Schematic overview of the
pSXN splicing reporter and construct used in this study, holding either HRAS wild type
sequence c.35_36GC>TG or c.36C>T or c.36C>Gmutated sequences (top). The pSXN
reporter contains an artificial small (34 bp) exon positioned between β-actin exon 1 and exon 2
as well as downstream exon 18 from cTNT. The natural sequence of β-actin intron 1 is inserted
on both sides of the middle exon. The reporter contains flanking Sall and BamHI restriction
sites for cloning. PCR analysis of splicing of pSXN-HRASminigenes in HepG2 cells (bottom).
(TIF)
S6 Fig. The c.35_36GC>TGmutation identified in the index individual with Costello syn-
drome disrupts an SRSF2 binding ESE and creates an hnRNPF/H binding ESS within exon
2. (a) Splicing ofHRAS exon 2 depends on SR-proteins like SRSF2 to be recognized by the spli-
ceosome due to a suboptimal 3’splice site. Binding of SRSF2 within exon 2 promotes its inclu-
sion in the HRASmRNA. (b) The c.35_36GC>TGmutation in exon 2 disrupts the ESE and
creates an ESS, which binds hnRNPF/H and thereby excludes inclusion of exon 2 in the
Splicing Efficiency of ActivatingHRASMutations
PLOS Genetics | DOI:10.1371/journal.pgen.1006039 May 19, 2016 15 / 18
mRNA, since it cannot be recognized by the spliceosome.
(TIF)
S7 Fig. Endogenous SRSF2 knock down in T24 cells. (a) PCR analysis of HRAS exon 2 skip-
ping reveals skipping in the context of SRSF2 knock down. (b) Western blot analysis confirmed
reduced levels of SRSF2 protein after knock down. β-actin was used as a control.
(TIF)
S8 Fig. Endogenous SRSF1 knock down in T24 cells. (a) PCR analysis reveals no effect on
splicing ofHRAS exon 2 after SRSF1 knock down. (b) Western blot analysis confirmed reduced
levels of SRSF1 protein after knock down.
(TIF)
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